100827-28-9 Usage
Uses
Used in Pharmaceutical Industry:
(E)-N-(2-(2,5-Dihydroxyphenyl)ethenyl)formamide is used as a potential therapeutic agent for its antioxidant properties, which may contribute to the development of treatments for various diseases and conditions associated with oxidative stress.
(E)-N-(2-(2,5-Dihydroxyphenyl)ethenyl)formamide is also used as a potential anti-inflammatory agent, which could be beneficial in the treatment of inflammatory diseases and conditions.
Additionally, due to its potential pharmaceutical properties, (E)-N-(2-(2,5-Dihydroxyphenyl)ethenyl)formamide is used in the research and development of new drugs for specific medical conditions, aiming to improve patient outcomes and quality of life.
Used in Chemical Research:
In the field of chemical research, (E)-N-(2-(2,5-Dihydroxyphenyl)ethenyl)formamide serves as a subject of interest for studying its unique chemical structure and properties. This research can lead to a better understanding of formamide derivatives and their potential applications in various industries, including pharmaceuticals, materials science, and more.
Check Digit Verification of cas no
The CAS Registry Mumber 100827-28-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,0,8,2 and 7 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 100827-28:
(8*1)+(7*0)+(6*0)+(5*8)+(4*2)+(3*7)+(2*2)+(1*8)=89
89 % 10 = 9
So 100827-28-9 is a valid CAS Registry Number.
InChI:InChI=1/C9H9NO3/c11-6-10-4-3-7-5-8(12)1-2-9(7)13/h1-6,12-13H,(H,10,11)/b4-3+
100827-28-9Relevant academic research and scientific papers
Use of endothelin conjugates in therapy, new endothelin conjugates, agents that contain the latter, and process for their production
-
, (2008/06/13)
This invention relates to the use of conjugates that consist of endothelins and active groups for therapy of vascular diseases as well as new endothelin conjugates, agents that contain these compounds and process for their production.
SYNTHESIS OF ERBSTATIN
Deshmukh, M. N.,Joshi, Shreerang V.
, p. 1483 - 1490 (2007/10/02)
A simple and convenient synthesis of the tyrosinespecific protein kinase inhibitor, erbstatin (1) from cheap and easily accessible 4-methoxyphenol is described.
TOTAL SYNTHESIS OF ERBSTATIN.
Dow, Robert L.,Flynn, Matthew J.
, p. 2217 - 2220 (2007/10/02)
Synthesis of the protein tyrosine kinase inhibitor, erbstatin (1), in 36percent overall yield from commercially available 2,5-dihydroxy cinnamic acid is described.
TOTAL SYNTHESIS OF ERBSTATIN
Hangauer, David G.
, p. 5799 - 5802 (2007/10/02)
The total synthesis of erbstatin in six steps and 38percent overall yield from commercially available lactone 1 is presented.
